SCHEMBL19670622

SCHEMBL19670622

CCN1CCCN(C(=O)Nc2cnn(C)c2)c2nc(-c3ccnc(C)c3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 2/20 0.40
▸ BTK Q06187 8/20 0.38
▸ WNT3A P56704 5/20 0.37
▸ RPS6KA3 P51812 2/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ PSEN1 P49768 1/20 0.35
▸ PSEN2 P49810 1/20 0.35
▸ APH1B Q8WW43 1/20 0.35
▸ NCSTN Q92542 1/20 0.35
▸ APH1A Q96BI3 1/20 0.35
▸ PSENEN Q9NZ42 1/20 0.35
▸ RPS6KA2 Q15349 1/20 0.35
▸ BUB1 O43683 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ HRH2 P25021 1/20 0.34
▸ CDK7 P50613 1/20 0.34
▸ CD69 Q07108 1/20 0.34
▸ AAK1 Q2M2I8 1/20 0.34
▸ MAP3K19 Q56UN5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19365813 0.90 RPS6KA3 (0.36) CSF1RBTKWNT3ARPS6KA3MAPK1
SCHEMBL19670620 0.88 HTR2A (0.38) WNT3APSEN1PSEN2APH1BNCSTN
SCHEMBL19670352 0.87 HTR2C (0.47) —
SCHEMBL19670571 0.86 NOTUM (0.39) CSF1RWNT3A
SCHEMBL19706092 0.86 CYP11B2 (0.37) WNT3APSEN1PSEN2APH1BNCSTN
SCHEMBL19670565 0.85 WNT3A (0.37) WNT3AMAPK1PSEN1PSEN2APH1B
SCHEMBL19670512 0.85 BTK (0.37) CSF1RBTKWNT3ARPS6KA3MAPK1
SCHEMBL19670124 0.84 WNT3A (0.40) CSF1RWNT3A
SCHEMBL19670591 0.83 FGFR4 (0.42) WNT3A
SCHEMBL19670569 0.82 FAAH (0.36) CSF1RWNT3ARPS6KA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20190048016-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-02-14 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 CSF1R 2306/4885BTK 678/4885WNT3A 4291/4885
US-20190048016-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 CSF1R 1955/4885BTK 702/4885WNT3A 4543/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 CSF1R 2306/4885BTK 678/4885WNT3A 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback